FI105023B - Förfarande för framställning av terapeutiskt användbara difenyl-4-perhydroisoindolderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara difenyl-4-perhydroisoindolderivat Download PDF

Info

Publication number
FI105023B
FI105023B FI944729A FI944729A FI105023B FI 105023 B FI105023 B FI 105023B FI 944729 A FI944729 A FI 944729A FI 944729 A FI944729 A FI 944729A FI 105023 B FI105023 B FI 105023B
Authority
FI
Finland
Prior art keywords
diphenyl
methoxyphenyl
radical
kpa
prepared
Prior art date
Application number
FI944729A
Other languages
English (en)
Finnish (fi)
Other versions
FI944729A (sv
FI944729A0 (sv
Inventor
Jean-Luc Malleron
Jean-Francois Peyronel
Daniel Achard
Serge Grisoni
Michael Tabart
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI944729A publication Critical patent/FI944729A/sv
Publication of FI944729A0 publication Critical patent/FI944729A0/sv
Application granted granted Critical
Publication of FI105023B publication Critical patent/FI105023B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

1. Pörfarande för framställning av terapeutiskt användbara difenyl-4-perhydroisoindolderivat med formeln 5 (I) och salter därav: « (I) N —C —CH —R,
10 Rr-k I r2 R3 R4 väri - symbolen R! är en fenylradikal, som eventuellt är sub-15 stituerad med hydroxi-, alkoxi- eller dialkylaminoradi- kaler, eller R1 är en indolylradikal, som kan vara sub-stituerad med halogen eller en alkyl- eller alkoxiradikal, eller R1 är naftyl, tienyl, indenyl eller bensotienyl, - symbolen R2 är en väteatom eller en hydroxi-, alkyl- 20 eller aminoradikal, - symbolen R3 är en fenylradikal, som eventuellt i 2-posi-tionen är substituerad med en alkyl- eller alkyloxiradikal med 1 eller 2 kolatomer, och - symbolen R4 är en fluoratom eller en hydroxiradikal, : 25 och symbolen Rs är en väteatom eller - symbolerna R4 och R5 är hydroxiradikaler, eller - symbolen R4 bildar tillsammans med R5 är en bindning, varvid ovannämnda alkylradikaler är rakkedjade eller förgrenade och innehäller 1-4 kolatomer, som racemiska 30 blandningar, stereoisomeriska former med strukturen: (Ia) TC- I N — C — CH — R, R3 R4 105023 64 i sinä (R) - eller (S)-former i kedjan -CHR^, eller i form av en blandning av flera av dessa former, kanne -tecknat av att (A) en syra med formeln II eller ett reaktivt derivat därav 5 Rj-CH-COOH (II) k väri R3 och R2 är säsom ovan definierats, omsätts med ett 10 isoindolderivat med den allmänna formeln:
15 NH (III) r5— r37 r4 väri symbolerna R3, R4 och Rs är säsom ovan definierats, ~ 20 varefter (Al) den erhällna föreningen, väri R4 är en hydroxiradikal och R5 är en väteatom, eventuellt omvandlas tili en förening, väri R4 är en fluoratom och Rs är en väteatom eller väri R4 och R5 tillsammans bildar en bindning, eller (B) för framställning av ett sädant perhydroisoin-: 25 dolderivat enligt patentkrav l, väri Rs är annat än en hydroxiradikal, omsätts en organometallförening med den allmänna formeln: R3-M 30 väri R3 är säsom ovan definierats, och M är litium, en radikal MgX eller CeX2, väri X är en halogenatom, med ett perhydroisoindolonderivat med den allmänna formeln 35 • · ••=3 : ~i « 105023 ob , 5 __^N —C—CH —R1 0 väri R* och R2 är säsom ovan definierats, varefter (Bl) den 10 erhällna alkoholen eventuellt omvandlas till ett per-hydroisoindolderivat, väri R4 är en fluoratom och Rs är en väteatom, eller till ett perhydroisoindolderivat, väri R4 och R5 tillsammans bildar en bindning, varefter (C) eventuellt separeras isomererna, och/eller (D) omvandlas den 15 erhällna föreningen till ett salt.
2. Förfarande enligt patentkrav 1, k ä n n e -tecknat av att man framställer 7,7-difenyl-4-(2-metoxifenyl)-2-[2-(2-metoxifenyl)propionyl]-4-perhydroiso-indolol. 20
3. Förfarande enligt patentkrav 1, k ä n n e - tecknat av att man framställer 7,7-difenyl-4-(2-metoxifenyl)-2- [2- (2-metoxifenyl)propionyl]perhydroisoin-dol-4,5-diol.
4. Förfarande enligt patentkrav 1, k ä n n e - : 25 tecknat av att man framställer 7,7-difenyl-4-(2- metoxifenyl)-2-[2-(2-hydroxifenyl) acetyl]-4-perhydroisoin-dolol.
5. Förfarande enligt patentkrav 1, k ä n n e -tecknat av att man framställer 7,7-difenyl-4 -(2 - 30 metoxifenyl)-2-(3-indolylacetyl)perhydroisoindol-4,5-diol.
, 6. Förfarande enligt patentkrav 1, k ä n n e - tecknat av att man framställer 7,7-difenyl-4-(2-metoxifenyl)-2-[(2-metoxifenyl)acetyl]-4-perhydroisoin-dolol. 35
7. Förfarande enligt patentkrav l, kanne- tecknat av att man framställer 7,7-difenyl-4-(2-metoxifenyl)-2-[2-(2-hydroxifenyl)propionyl]-4-perhydro-isoindolol.
FI944729A 1992-04-10 1994-10-07 Förfarande för framställning av terapeutiskt användbara difenyl-4-perhydroisoindolderivat FI105023B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9204390 1992-04-10
FR929204390A FR2689888B1 (fr) 1992-04-10 1992-04-10 Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR9300352 1993-01-15
PCT/FR1993/000352 WO1993021155A1 (fr) 1992-04-10 1993-04-08 Derives de perhydroisoindole comme antagonistes de la substance p

Publications (3)

Publication Number Publication Date
FI944729A FI944729A (sv) 1994-10-07
FI944729A0 FI944729A0 (sv) 1994-10-07
FI105023B true FI105023B (sv) 2000-05-31

Family

ID=9428707

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944729A FI105023B (sv) 1992-04-10 1994-10-07 Förfarande för framställning av terapeutiskt användbara difenyl-4-perhydroisoindolderivat

Country Status (24)

Country Link
US (1) US5484804A (sv)
EP (1) EP0635003B1 (sv)
JP (1) JP3205557B2 (sv)
KR (1) KR950700880A (sv)
AT (1) ATE167472T1 (sv)
AU (1) AU667214B2 (sv)
CA (1) CA2133840A1 (sv)
CZ (1) CZ284213B6 (sv)
DE (1) DE69319235T2 (sv)
DK (1) DK0635003T3 (sv)
ES (1) ES2118232T3 (sv)
FI (1) FI105023B (sv)
FR (1) FR2689888B1 (sv)
HU (1) HUT71354A (sv)
IL (1) IL105255A (sv)
MX (1) MX9301986A (sv)
NO (1) NO300417B1 (sv)
NZ (1) NZ251730A (sv)
PL (1) PL172754B1 (sv)
RU (1) RU2127260C1 (sv)
SK (1) SK279032B6 (sv)
TW (1) TW234119B (sv)
WO (1) WO1993021155A1 (sv)
ZA (1) ZA932527B (sv)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
FR2703679B1 (fr) * 1993-04-05 1995-06-23 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
TW365603B (en) * 1993-07-30 1999-08-01 Rhone Poulenc Rorer Sa Novel perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them
FR2710913B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2709752B1 (fr) * 1993-07-30 1995-10-06 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2710842B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouvelle application thérapeutique de dérivés de perhydroisoindole.
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
FR2727411B1 (fr) * 1994-11-30 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
FR2737495B1 (fr) * 1995-08-02 1997-08-29 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
AU737019B2 (en) * 1997-08-04 2001-08-09 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
US7101547B1 (en) 1999-01-22 2006-09-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
ES2304984T3 (es) 1999-11-03 2008-11-01 Amr Technology, Inc. Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP5007226B2 (ja) 2004-07-15 2012-08-22 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリンならびにノルエピネフリン、ドーパミン、およびセロトニンの再取り込みを遮断するためのその利用方法
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
CN108676800B (zh) 2010-08-17 2022-11-11 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR514273A (fr) * 1920-04-23 1921-03-07 Georges Loutz Bougie d'allumage électrique pour moteurs à explosions
US4042707A (en) * 1976-02-19 1977-08-16 E. I. Du Pont De Nemours And Company 3α-Arylhydroisoindoles
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676442B1 (fr) * 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2689889B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, et leur preparation.

Also Published As

Publication number Publication date
JP3205557B2 (ja) 2001-09-04
CZ248294A3 (en) 1995-11-15
RU2127260C1 (ru) 1999-03-10
NO943692L (no) 1994-10-03
DK0635003T3 (da) 1999-02-15
ZA932527B (en) 1993-11-08
HU9402911D0 (en) 1995-01-30
EP0635003A1 (fr) 1995-01-25
HUT71354A (en) 1995-11-28
IL105255A0 (en) 1993-08-18
AU667214B2 (en) 1996-03-14
CA2133840A1 (fr) 1993-10-28
CZ284213B6 (cs) 1998-09-16
FI944729A (sv) 1994-10-07
NO943692D0 (no) 1994-10-03
RU94045855A (ru) 1996-09-10
FR2689888B1 (fr) 1994-06-10
MX9301986A (es) 1994-05-31
US5484804A (en) 1996-01-16
NZ251730A (en) 1995-08-28
ES2118232T3 (es) 1998-09-16
DE69319235D1 (de) 1998-07-23
DE69319235T2 (de) 1999-01-07
TW234119B (sv) 1994-11-11
WO1993021155A1 (fr) 1993-10-28
SK279032B6 (sk) 1998-05-06
KR950700880A (ko) 1995-02-20
PL172754B1 (pl) 1997-11-28
ATE167472T1 (de) 1998-07-15
EP0635003B1 (fr) 1998-06-17
FR2689888A1 (fr) 1993-10-15
AU3956593A (en) 1993-11-18
JPH07505410A (ja) 1995-06-15
IL105255A (en) 1997-02-18
SK122094A3 (en) 1995-05-10
NO300417B1 (no) 1997-05-26
FI944729A0 (sv) 1994-10-07

Similar Documents

Publication Publication Date Title
FI105023B (sv) Förfarande för framställning av terapeutiskt användbara difenyl-4-perhydroisoindolderivat
EP0711280B1 (fr) Derives de perhydroisoindole comme antagonistes de la substance p
US5102667A (en) Isoindolone derivatives, their preparation and the pharmaceutical compositions containing them
EP0586490B1 (fr) Derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
HUT70490A (en) Novel thiopyranopyrrole derivatives, pharmaceutical compositions containing them and process for preparing them
US5739351A (en) Perhydroisoindole derivatives as substance P antagonists
HUT65590A (en) Novel derivatives of thiopyranopyrrole and preparation thereof
HU214574B (hu) Eljárás izoindolonszármazékok előállítására
FI105022B (sv) Nya difenyl-4-perhydroisoindolderivat, deras framställning och användning
CZ258495A3 (en) Novel derivatives of perhydroisoindole, process of their preparation and pharmaceutical compositions containing thereof